

No Evidence for Association Between the Functional rs1862513 Polymorphism in the Promoter Region of the Resistin Gene (RETN) and Pulmonary Tuberculosis in Northern Spain

Ocejo-Vinyals JG^{1*}, Escobio A², Irure-Ventura J¹, Ausin F¹, Arroyo JL³, Agüero R⁴, and Fariñas MC⁵¹Immunology, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain²Faculty of Biology, University of Oviedo, Spain³Bank Regional Blood and Tissue, Cantabria, Spain⁴Department of Pneumology, Hospital Universitario Marqués de Valdecilla, Santander, Spain⁵Infectious Diseases Unit, Hospital Universitario Marqués de Valdecilla-University of Cantabria, Santander, Spain

*Corresponding author: Ocejo-Vinyals JG, Immunology, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, Tel: +34942202941; E-mail: jgocejo@humv.es

Received date: February 06, 2015; Accepted date: February 27, 2015; Published date: February 28, 2015

Copyright: © 2015 Ocejo-Vinyals JG. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Background: Elevated levels of circulating Resistin, a peptide hormone produced by adipocytes in rodents but also by monocytes and macrophages in humans, has been reported in patients with tuberculosis infection. To date, only a few studies mainly focused in conditions such as diabetes, obesity, and cardio-metabolic risk have treated to analyse the role of single nucleotide polymorphisms in the Resistin Gene (RETN). However, polymorphisms in this gene have not been previously tested in pulmonary tuberculosis susceptibility.

Methods: The rs1862513 (-420C>G), a functional polymorphism in the RETN gene, which has been found to increase circulating resistin levels, was analysed in 192 patients with pulmonary tuberculosis, all of them HIV negative, and in 245 healthy individuals from a well genetically conserved Spanish population.

Results: Significant differences in genotype and allele frequencies of the rs1862513 functional polymorphism were not observed between patients and normal controls.

Conclusion: Our results would indicate that RETN rs1862513 would not play a major role in the susceptibility to pulmonary tuberculosis at least in our population in a well-powered study.

Keywords: Resistin; RETN; Single nucleotide polymorphism; Pulmonary tuberculosis; Susceptibility

Abbreviations

TB: Tuberculosis, Mtb: *Mycobacterium tuberculosis*, PTB: Pulmonary Tuberculosis, SNP: Single Nucleotide Polymorphism

Introduction

Tuberculosis (TB) is still a leading cause of death in humans and therefore remains a global health problem. *Mycobacterium tuberculosis* (MTB) infects approximately one-third of the human population. In 2013, there were an estimated 9.0 million cases and 1.5 million deaths [1]. Among people with pulmonary TB (PTB), those from South-East Asia, Western Pacific and African regions account for three quarters. Spain is one of the European countries with the highest rates of incidence and prevalence of TB. Approximately, 10% of individuals infected with MTB develop active pulmonary disease, suggesting that there exist differences in susceptibility or resistance to progression.

Susceptibility to TB seems to be multifactorial, resulting of complex interactions between host, pathogen, environmental and genetic

factors. To date, numerous host genes have been reported to be involved in this process [2-4].

Resistin, acronym derived from resistance to insulin, was initially found to be expressed in adipocytes in mice, and described as an adipokine known as adipose tissue-specific secretory factor, involved in lipid and glucose metabolism [5-7]. Further studies, revealed that in humans, resistin was predominantly expressed and secreted by monocytes and macrophages acting as a pro-inflammatory cytokine [8]. Moreover, plasma concentrations of resistin and resistin-like molecules have been found significantly increased in different types of infections and it has been proposed as a biomarker of sepsis severity [9-13].

Regarding TB, a few studies have been conducted focused on correlating circulating resistin levels with severity, or as a surrogate biomarker for monitoring TB disease [14-16]. Several studies have investigated the different SNPs of the RETN gene identifying the rs1862513 SNP (-420 C/G) in the promoter region of RETN as the main determinant of circulating resistin concentration in humans [17,18].

Due to the lack of previous studies regarding the role of this SNP in PTB, the aim of this work was to elucidate if this SNP could be

associated with susceptibility to PTB in a well genetically conserved population (Cantabria, Northern Spain).

Materials and Methods

Study population

Through a case-control study, patients with PTB (n=192) and age and sex matched healthy controls (n=245) entered this research. Both controls and patients were of Caucasian background, all of them from Cantabria region (Northern Spain). Diagnosis of PTB was clinically confirmed by X-rays, and bacteriologically assessed using both sputum smear examination and culture. The presence of active or latent infection in the control group was ruled out by performing an interferon-gamma release assay (QuantiFERON-TB Gold In-Tube). All subjects were HIV-negative and they did not presented any autoimmune disease.

Procedures used in the study conformed to the principles outlined in the Declaration of Helsinki. All samples were collected with the written consent of the participants. The study protocol was accepted and approved by the Research Ethics Board of the Hospital.

Genotyping

DNA samples were prepared from whole blood by using the Maxwell 16 Blood DNA Purification Kit (Promega Biotech Ibérica, S.L., Spain) following the manufacturer's instructions.

Genotyping of the RETN rs1862513 (-420 C/G), was performed by a TaqMan SNP Genotyping Assays (Life Technologies S.A., Madrid, Spain) in an ABI PRISM 7900 HT sequence detection systems (Life Technologies).

Statistical analysis

For the statistical analysis, the results were processed with the SPSS computer package (version 12). Allele and genotype frequencies were estimated by direct counting, and the χ^2 test was used to identify significant departure from the Hardy-Weinberg equilibrium. Comparison of frequencies between PTB patients and healthy controls was carried out using the χ^2 test with Yates correction. The multiple inheritance models (dominant, recessive or log-additive models) were analysed by using the web tool SNPStats [19].

Statistical power of the present study sample size was calculated by using the PS Power and Sample Size Calculations software version 3.0.

Clinical profile	PTB patients (n=192)	Controls (n=245)
Age (y), mean (range)	42.7 (19-64)	38.8 (18-65)
Sex (male/female)	120/72	152/93
Origin	Cantabria (Northern Spain)	Cantabria (Northern Spain)

Table 1: Clinical and demographic features of PTB patients and healthy controls included in the study.

Results

Clinical and demographic characteristics of both PTB patients and healthy controls are shown in Table 1. Allele and genotype frequencies

were all in Hardy-Weinberg equilibrium (controls $\chi^2=2.21$, $p=0.14$, patients $\chi^2=0.11$, $p=0.73$). The statistical power for detecting an odds ratio (OR) ≥ 2 . Allele frequencies are given in Table 2 and Table 3.

Allele	PTB patients (n=192)	Controls (n=245)	p	OR	95% CI
-420 C	273 (71.09) ^{a, b}	330 (67.35)	0.26 ^c	1.19	0.89-1.59
-420 G	111 (28.91)	160 (32.65)			

Table 2: Allelic frequencies of RETN rs1862513 SNP in PTB patients and healthy controls. ^aThe data are expressed as absolute numbers and percentages in parenthesis. ^bThe sum of the absolute numbers of the two alleles of each SNP is twice the number of patients and controls. ^cThe study has 99% power for detecting an odds ratio (OR) ≥ 2 .

RTN Genotype	PTB patients (n=192) n%	Controls (n=245) n%	p	OR	95% CI
CC	98 (51.04)	106 (43.27)	0.13	1.37	0.94-2.00
CG	77 (40.10)	118 (48.16)	0.11 ^a	0.72	0.49-1.06
GG	17 (8.86)	21 (8.57)	0.95	1.04	0.53-2.02

Table 3: Comparison of genotype frequencies of RETN rs1862513 SNP in patients with PTB and in healthy controls. ^aThe study had >90% power for detecting an odds ratio (OR) ≥ 2 for the CC and CG genotypes, and 60% for the GG genotype.

We did not find a significant difference in the distribution of the two alleles between PTB patients and controls (Table 1). In the same way, no significant association was found when we compared genotypes (Table 2) neither when we analysed the dominant, recessive nor log-additive models (data not shown).

Discussion

In this study, we have investigated for the first time the role of the functional SNP, rs1862513 (-420 C/G) in the promoter region of RETN in conferring susceptibility or resistance to PTB. Although we did not find any association, our results showed to be statistically well-powered.

To date, resistin levels or the role of this SNP have been studied and associated with different conditions, such as cardiovascular diseases, insulin resistance, type 2 diabetes, periodontal inflammation and serious infections among others [5,7,9-13,18,20-22]. In these studies, the G allele and/or the GG genotype were associated with higher circulating resistin levels.

Regarding type-2 diabetes and obesity, two recent meta-analysis have demonstrated a lack of correlation of this SNP with this disease [23,24]. The authors conclude that this lack of association might be due to a small pooled sample size.

Another explanation of this lack of association could be due to the fact that circulating resistin levels would be influenced by other genetic variants in different genes [25].

Regarding PTB a few studies have focused on the relationship between resistin and the disease. One of them studied the utility of measuring circulating resistin levels as a sensitive biomarker to determine TB treatment end points concluding that this molecule would be a surrogate marker for TB treatment. Furthermore, resistin could be useful as an early prognostic biomarker for monitoring TB disease onset [16]. Another study suggested that increased resistin levels in patients with diabetes mellitus and severe TB might act directly in macrophages suppressing the Mtb-induced inflammasome activation through inhibiting reactive oxygen species production by leukocytes [14]. This could explain an increased susceptibility to pulmonary tuberculosis.

Interestingly, an increased expression of RETN in lung tissue has been observed in Glässer's disease in pigs (a respiratory disease produced by *Haemophilus parasuis* infection which can affect other organs) [26]. The results of these studies would support the role of resistin in conferring susceptibility or resistance against pulmonary infection, probably mediated through an inhibition of macrophage function.

To our knowledge, this is the first report on investigating the relationship between a functional SNP in the RETN gene and susceptibility to PTB. We could conclude that this SNP would not influence susceptibility or resistance to PTB, at least in our population. However, it should be considered the influence of ethnic differences in genetic polymorphisms which could determine their functions in the different populations. Thus, the relationship between this SNP and PTB would need further studies to elucidate if it would play a role in the pathogenesis of PTB.

References

1. WHO Report (2014) Global Tuberculosis Report. World Health Organization. Geneva, Switzerland.
2. Schurr E (2011) The contribution of host genetics to tuberculosis pathogenesis. *Kekkaku* 86: 17-28.
3. Selvaraj P, Alagarasu K, Raghavan S (2013) Genetics of Susceptibility to Mycobacterial Disease. In: eLS. John Wiley & Sons Ltd, Chichester.
4. Ocejo-Vinyals JG, Ausín F, Puente de Mateo E, Arroyo JL, Agüero R, et al. (2013) Association of Human Leukocyte Antigen Class I and II Variants with Susceptibility to Pulmonary Tuberculosis in a Caucasian Population from Northern Spain. *J Mycobact Dis* 3: 132.
5. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, et al. (2001) The hormone resistin links obesity to diabetes. *Nature* 409: 307-312.
6. Junkin KA, Dyck DJ, Mullen KL, Chabowski A, Thrush AB (2009) Resistin acutely impairs insulin-stimulated glucose transport in rodent muscle in the presence, but not absence, of palmitate. *Am J Physiol Regul Integr Comp Physiol* 296: R944-951.
7. McTernan PG, Fisher FM, Valsamakis G, Chetty R, Harte A, et al. (2003) Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. *J Clin Endocrinol Metab* 88: 6098-6106.
8. Patel L, Buckels AC, Kinghorn JJ, Murdock PR, Holbrook JD, et al. (2003). Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. *Biochem Biophys Res Commun* 300: 472-476.
9. Hillenbrand A, Knippschild U, Weiss M, Schrezenmeier H, Henne-Bruns D, et al. (2010) Sepsis induced changes of adipokines and cytokines-septic patients compared to morbidly obese patients. *BMC Surg* 10: 26.
10. Mazaki-Tovi S, Vaisbuch E, Romero R, Kusanovic JP, Chaiworapongsa T, et al. (2010) Hyperresistinemia—a novel feature in systemic infection during human pregnancy. *Am J Reprod Immunol* 63: 358-369.
11. Cekmez F, Canpolat FE, Cetinkaya M, Aydinöz S, Aydemir G, et al. (2011) Diagnostic value of resistin and visfatin, in comparison with C-reactive protein, procalcitonin and interleukin-6 in neonatal sepsis. *Eur Cytokine Netw* 22: 113-117.
12. Wagner TA, Gravett CA, Healy S, Soma V, Patterson JC, et al. (2011) Emerging biomarkers for the diagnosis of severe neonatal infections applicable to low-resource. *J Glob Health* 1: 210-223.
13. Irvin AD, Marriage F, Mankambo LA, IPD Group Study, Jeffers G, et al (2012) Novel biomarker combination improves the diagnosis of serious bacterial infections in Malawian children. *BMC Medical Genomics* 5: 13.
14. Chao WC, Yen CL, Wu YH, Chen SY, Hsieh CY, et al. (2014) Increased resistin may suppress reactive oxygen species production and inflammasome activation in type 2 diabetic patients with pulmonary tuberculosis infection. *Microbes Infect* pii: S1286-4579(14)00305-0.
15. Chang SW, Pan WS, Lozano Beltran D, Oleyda Baldeomar L, Solano MA et al. (2013) Gut hormones, appetite suppression and cachexia in patients with pulmonary TB. *PLoS One* 8: e54564.
16. Ehtesham NZ, Nasiruddin M, Alvi A, Kumar BK, Ahmed N, et al. (2011) Treatment end point determinants for pulmonary tuberculosis: human resistin as a surrogate biomarker. *Tuberculosis (Edinb)* 91: 293-299.
17. Cho YM, Youn BS, Chung SS, Kim KW, Lee HK, et al. (2004) Common genetic polymorphisms in the promoter of resistin gene are major determinants of plasma resistin concentrations in humans. *Diabetologia* 47: 559-565.
18. Kumar S, Gupta V, Srivastava N, Gupta V, Mishra S et al. (2014) Resistin 420 C/G gene polymorphism on circulating resistin, metabolic risk factors and insulin resistance in adult women. *Immunology Letters* 162: 287-291.
19. Sole X, Guino E, Valls J, Iniesta R, Moreno V (2006) SNPStats: a web tool for the analysis of association studies. *Bioinformatics* 22: 1928-1929.
20. Hernández-Romero D, Orenes-Piñero E, García-Honrubia A, Climent V, Romero-Aniorte AI, et al. (2014) Involvement of the -420C>G RETN polymorphism in myocardial fibrosis in patients with hypertrophic cardiomyopathy. *J Intern Med* Dec 4.
21. Patel SP, Raju PA (2013) Resistin in serum and gingival crevicular fluid as a marker of periodontal inflammation and its correlation with single-nucleotide polymorphism in human resistin gene at -420. *Contemp Clin Dent* 4: 192-197.
22. Patel SP, Raju PA (2014) Gingival crevicular fluid and serum levels of resistin in obese and non-obese subjects with and without periodontitis and association with single-nucleotide polymorphism in human resistin gene at -420. *J Indian Soc Periodontol* 18: 555-559.
23. Wen Y, Lu P, Dai L (2013) Association between resistin gene -420 C/G polymorphism and the risk of type 2 diabetes mellitus: a meta-analysis. *Acta Diabetol* 50: 267-272.
24. Yu Z, Han S, Cao X, Zhu C, Wang X et al. (2012) Genetic polymorphism in adipokine genes and the risk of obesity: a systematic review and meta-analysis. *Obesity (Silver Spring)* 20: 396-406.
25. Qi Q, Menzaghi C, Smith S, Liang L, de Rekeneire N, et al. (2012) Genome-wide association identifies TYW3/CRYZ and NDST4 loci associated with circulating resistin levels. *Hum Mol Genet* 21: 4774-4780.
26. Wilkinson JM, Sargent CA, Galina-Pantoja L, Tucker AW (2010) Gene expression profiling in the lungs of pigs with different susceptibilities to Glässer's disease. *BMC Genomics* 11: 455.